# Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors

> **NCT06797362** · — · AVAILABLE · sponsor: **Nuvalent Inc.**

## Conditions studied

- Non Small Cell Lung Cancer
- ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** NVL-520

## Key facts

- **NCT ID:** NCT06797362
- **Lead sponsor:** Nuvalent Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06797362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06797362, "Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06797362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*